Standout Papers

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-la... 2020 2026 2022 2024927
  1. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (2020)
    Ghassan K. Abou‐Alfa, Vaibhav Sahai et al. The Lancet Oncology

Immediate Impact

55 standout
Sub-graph 1 of 20

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
23 intermediate papers

Works of David Gallinson being referenced

O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
2022
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
David Gallinson 603 775 318 364 17 1.1k
Chaitanya Churi 658 807 286 287 8 1.0k
Josep R. Germà 512 322 356 323 29 1.1k
Jerrold B. Teitcher 365 513 311 345 22 1.3k
Marta Orsenigo 796 393 293 579 25 1.3k
Shoko Ohashi 494 746 249 240 8 933
Tomoki Shirota 765 1092 387 326 19 1.4k
Lucio Giustini 864 316 382 401 41 1.3k
Clara Montagut 701 350 179 225 13 914
Kazuhiko Yonekura 761 291 468 617 23 1.3k
Yuichi Arimoto 374 420 329 307 34 1.0k

All Works

Loading papers...

Rankless by CCL
2026